In the CARNIVAL Type I trial, researchers led by Bostons Massachusetts General Hospital set out to investigate the safety and therapeutic potential of VPA, combined with L-carnitine, in infants with SMA
These included weight gain, increased weight of visceral organs, and potentially improved feed efficiency when the murine models were exposed to it continuously
Intriguingly, different transport modes have been described for OCTN2, either murine or human, namely a Na + -carnitine symport and a Na + -dependent carnitine/acylcarnitine antiport (Ohashi et al., 2001
Tyni T, Kivela T, Lappi M, Summanen P, Nikoskelainen E, Pihko H: Ophthalmologic findings in long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency caused by the G1528C mutation: a new type of hereditary metabolic chorioretinopathy